Opening Iatrogenic Immune-Mediated CNS Disorders by Dr. Nikolay Neofidov, PGY4
Iatrogenic Immune-Mediated CNS Disorders by Dr. Nikolay Neofidov, PGY4
- Length
- 1 h 7 min
- Level
- Undergraduate
- Recorded
- University of Louisville2026
Chapter 1 of 11: Before the lecture
Traces neurological adverse events from biological therapies like immune checkpoint inhibitors.
Iatrogenic immune-mediated central nervous system disorders trace the neurological adverse events of biological therapies including immune checkpoint inhibitors and CAR T-cell treatments. The presentation examines the physiological mechanisms of these disorders, such as epitope spreading, molecular mimicry, and cytokine release syndrome. Neofidov outlines diagnostic evaluation pathways using magnetic resonance imaging and cerebrospinal fluid analysis, detailing grading scales for immune neurotoxicity. Management strategies are evaluated across specific conditions like meningitis, encephalitis, and ICANS, comparing the efficacy of targeted biological agents and corticosteroids.
Iatrogenic immune-mediated central nervous system disorders trace the neurological adverse events of biological therapies including immune checkpoint inhibitors and CAR T-cell treatments. The presentation examines the physiological mechanisms of these disorders, such as epitope spreading, molecular mimicry, and cytokine release syndrome. Neofidov outlines diagnostic evaluation pathways using magnetic resonance imaging and cerebrospinal fluid analysis, detailing grading scales for immune neurotoxicity. Management strategies are evaluated across specific conditions like meningitis, encephalitis, and ICANS, comparing the efficacy of targeted biological agents and corticosteroids.
Impact of Immune Checkpoint Inhibitors on the Course of Multiple Sclerosis
Quin at (2024)
Quin et al (2024)
Society for Immunotherapy of Cancer (SITC) clinical practice guideline
Common Terminology Criteria for Adverse Events (CTCAE v5.0)
Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2
This lecture
Talk 8 of 115 of UofL Neurology Grand Rounds.
Choose a node to see how it connects to this lecture. What comes before is on the leftat the top. What comes after is on the rightat the bottom. The ring is what it teaches. People and places are above. Other lectures and books are below.
Press a chosen node again to open it.
Your comment is kept while you sign up.Sign in
TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study
Iatrogenic immune-mediated CNS disorders
Fatal neurotoxicity after chimeric antigen receptor T-cell therapy: An unexpected case of fludarabine-associated progressive leukoencephalopathy
Demyelinating Neurological Adverse Events following the Use of Anti-TNF-a Agents
Neurological Complications Associated with Immune Checkpoint Inhibitors
BCMA CAR-T cell therapy with ide-cel in relapsed or refractory multiple myeloma
Directed CAR-T Cells in ART with Refractory MOGAD
CAR-T cells for treating autoimmune diseases
Products produced to treat cardiac injury